Drug interactions
Eluxadoline + Metformin-repaglinide
Severity: Moderate
Eluxadoline and Metformin-repaglinide: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Repaglinide may inhibit OATP1B1 and raise eluxadoline exposure, which increases the risk of eluxadoline adverse effects such as constipation, nausea and pancreatitis.
What this interaction means in plain words
Eluxadoline and Metformin-repaglinide can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Eluxadoline belongs to Gastrointestinal Tract; Metformin-repaglinide belongs to Endocrine.
Why it happens
OATP1B1 inhibition by repaglinide reduces hepatic uptake of eluxadoline.
What to do
Reduce eluxadoline to 75 mg twice daily as labeled with OATP1B1 inhibitors and monitor for gastrointestinal and pancreatic adverse effects.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Eluxadoline and Metformin-repaglinide, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Metformin-repaglinide
Other interactions of Eluxadoline
Frequently asked questions
Can I take Eluxadoline with Metformin-repaglinide?
MediHelp rates the interaction as moderate. Eluxadoline and Metformin-repaglinide can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Repaglinide may inhibit OATP1B1 and raise eluxadoline exposure, which increases the risk of eluxadoline adverse effects such as constipation, nausea and pancreatitis.
How serious is the interaction between Eluxadoline and Metformin-repaglinide?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Reduce eluxadoline to 75 mg twice daily as labeled with OATP1B1 inhibitors and monitor for gastrointestinal and pancreatic adverse effects.
What other medicines interact with Metformin-repaglinide?
MediHelp also lists interactions of Metformin-repaglinide with, for example, Gemfibrozil, Apalutamide, Clarithromycin. The full list is on the Metformin-repaglinide page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
